References
- SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
- DeSantisCELinCCMariottoABCancer treatment and survivorship statistics, 2014CA Cancer J Clin201464425227124890451
- TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
- LaurieSAGossGDRole of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancerJ Clin Oncol20133181061106923401452
- QiWXShenZLinFComparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysisAsian Pac J Cancer Prev201213105177518223244131
- HerbstRSHeymachJVLippmanSMLung cancerN Engl J Med2008359131367138018815398
- HuangSFLiuHPLiLHHigh frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in TaiwanClin Cancer Res200410248195820315623594
- FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol201129212866287421670455
- HanJYParkKKimSWFirst-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
- ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
- RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
- ShiYAuJSThongprasertSA prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)J Thorac Oncol20149215416224419411
- WangSWangZEGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysisInt J Clin Exp Med2014781967197825232377
- ZhangLYangHZhaoYDetection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technologyCurr Drug Metab20121371007101122591345
- RenGJZhaoYYZhuYJTumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancerChin Med J (Engl)20111241192521362302
- MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
- MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
- JannePAWangXSocinskiMARandomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trialJ Clin Oncol201230172063206922547605